Skip to content


Immunotherapy Biomarkers

Section edited by Lisa H. Butterfield, PhD

Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.

  1. Content type: Review

    Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomark...

    Authors: Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif and Ena Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:138

    Published on:

  2. Content type: Research article

    A high density of tumor-infiltrating CD8+ T cells and CD20+ B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma (HGSC). Howev...

    Authors: Iva Truxova, Lenka Kasikova, Michal Hensler, Petr Skapa, Jan Laco, Ladislav Pecen, Lucie Belicova, Ivan Praznovec, Michael J. Halaska, Tomas Brtnicky, Eva Salkova, Lukas Rob, Roman Kodet, Jeremy Goc, Catherine Sautes-Fridman, Wolf Herman Fridman…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:139

    Published on:

  3. Content type: Research article

    Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specifi...

    Authors: Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian and Paul Nghiem

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:131

    Published on:

  4. Content type: Research article

    Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lu...

    Authors: Aixa E. Soyano, Bhagirathbhai Dholaria, Julian A. Marin-Acevedo, Nancy Diehl, David Hodge, Yan Luo, Rami Manochakian, Saranya Chumsri, Alex Adjei, Keith L. Knutson and Yanyan Lou

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:129

    Published on:

  5. Content type: Research article

    We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified.

    Authors: Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:99

    Published on:

  6. Content type: Research article

    Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk d...

    Authors: Philip Friedlander, Kevin Wood, Karl Wassmann, Alan M. Christenfeld, Nina Bhardwaj and William K. Oh

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:90

    Published on:

  7. Content type: Research article

    Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint i...

    Authors: Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò and Paolo Antonio Ascierto

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:74

    Published on:

  8. Content type: Research article

    Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acqui...

    Authors: Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross and Maria E. Cabanillas

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:68

    Published on:

  9. Content type: Research article

    The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enric...

    Authors: Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola and Alessandra Cesano

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:63

    Published on:

  10. Content type: Research article

    Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive ...

    Authors: Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Devin Dressman, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Moachun Qin, Yirong Wang, Felicia L. Lenzo, Angela Omilian, Wiam Bshara, Matthew Zibelman…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:32

    Published on:

  11. Content type: Research article

    Microsatellite instability (MSI) is now being used as a sole biomarker to guide immunotherapy treatment for men with advanced prostate cancer. Yet current molecular diagnostic tests for MSI have not been evalu...

    Authors: Jennifer A. Hempelmann, Christina M. Lockwood, Eric Q. Konnick, Michael T. Schweizer, Emmanuel S. Antonarakis, Tamara L. Lotan, Bruce Montgomery, Peter S. Nelson, Nola Klemfuss, Stephen J. Salipante and Colin C. Pritchard

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:29

    Published on:

  12. Content type: Research article

    One of today’s greatest hurdles for cancer immunotherapy is the absence of information regarding which tumor antigens are already recognized by patients receiving immunotherapies, and whether those therapies t...

    Authors: Tyler W. Hulett, Shawn M. Jensen, Phillip A. Wilmarth, Ashok P. Reddy, Carmen Ballesteros-Merino, Michael E. Afentoulis, Christopher Dubay, Larry L. David and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:27

    Published on:

  13. Content type: Research article

    While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy...

    Authors: Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, Anita Giobbie-Hurder, Mariano Severgnini, Jun Zhou, Michael Manos, Lauren M. Eastman, Holden T. Maecker and F. Stephen Hodi

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:18

    Published on:

  14. Content type: Research article

    Immuno-oncology and cancer immunotherapies are areas of intense research. The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important measures of the immune response to cancer with pr...

    Authors: Keith E. Steele, Tze Heng Tan, René Korn, Karma Dacosta, Charles Brown, Michael Kuziora, Johannes Zimmermann, Brian Laffin, Moritz Widmaier, Lorenz Rognoni, Ruben Cardenes, Katrin Schneider, Anmarie Boutrin, Philip Martin, Jiping Zha and Tobias Wiestler

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:20

    Published on:

  15. Content type: Research article

    The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objectives: 1- Design a sliding scale to grade survival in...

    Authors: Helmy M. Guirgis

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:15

    Published on:

  16. Content type: Research article

    It remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in ...

    Authors: Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F. Quigley, James Heath, Rong Fan, Sean Mackay, Mark E. Dudley, Sadik H. Kassim and Jing Zhou

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:85

    Published on:

  17. Content type: Research article

    Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the de...

    Authors: Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:81

    Published on:

  18. Content type: Research article

    There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocy...

    Authors: Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana and Ulka Vaishampayan

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:82

    Published on:

  19. Content type: Research article

    Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to...

    Authors: Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj and William K. Oh

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:67

    Published on:

  20. Content type: Research article

    Immunotherapies have demonstrated clinical benefit for many types of cancers, however many patients do not respond, and treatment-related adverse effects can be severe. Hence many efforts are underway to ident...

    Authors: Laura E. Johnson, Brian M. Olson and Douglas G. McNeel

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:56

    Published on:

  21. Content type: Research article

    Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...

    Authors: Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:33

    Published on:

  22. Content type: Meeting report

    This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...

    Authors: James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:29

    Published on:

  23. Content type: Research article

    Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...

    Authors: James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:25

    Published on:

  24. Content type: Research article

    Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...

    Authors: Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem and Steven P. Fling

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:18

    Published on:

  25. Content type: Research article

    Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...

    Authors: Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:20

    Published on:

  26. Content type: Research article

    Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels...

    Authors: Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A. Perez and Constantin N. Baxevanis

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:75

    Published on:

  27. Content type: Review

    Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibi...

    Authors: Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield and Magdalena Thurin

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:76

    Published on:

  28. Content type: Review

    There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical...

    Authors: Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael Hawtin, Sylvia Janetzki, Ilan Kirsch, Giuseppe V. Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Jenny Zhang, Lisa H. Butterfield and Magdalena Thurin

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:77

    Published on:

  29. Content type: Research article

    Preclinical studies suggest a synergistic effect between radiation, immunotherapy and anti-angiogenic therapy, although the mechanisms are unclear. Angiogenic cytokines are known to affect the immune system, a...

    Authors: Vishwajith Sridharan, Danielle N. Margalit, Stephanie A. Lynch, Mariano Severgnini, F. Stephen Hodi, Robert I. Haddad, Roy B. Tishler and Jonathan D. Schoenfeld

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:32

    Published on:

  30. Content type: Research article

    Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior ...

    Authors: Jason J. Luke, Yuanyuan Zha, Karen Matijevich and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:35

    Published on:

  31. Content type: Research article

    Adoptive T cell therapy (ACT) has shown great promise in melanoma, with over 50 % response rate in patients where autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) can be cultured and expanded. A ...

    Authors: Zipei Feng, Sachin Puri, Tarsem Moudgil, William Wood, Clifford C. Hoyt, Chichung Wang, Walter J. Urba, Brendan D. Curti, Carlo B. Bifulco and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:47

    Published on:

  32. Content type: Research article

    Treating elderly breast cancer patients remains a challenge but the increasing availability of immunotherapeutic approaches instills optimism that these tumours may also be susceptible to immune control. Becau...

    Authors: Jithendra Kini Bailur, Evelyna Derhovanessian, Brigitte Gueckel and Graham Pawelec

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:45

    Published on:

  33. Content type: Short report

    Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Henc...

    Authors: Kevin K. Dobbin

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:40

    Published on:

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2015 3:56

  34. Content type: Research article

    We evaluated candidate circulating serum cytokines, chemokines and growth factors in patients with locally/regionally advanced melanoma receiving neoadjuvant ipilimumab with toxicity and clinical outcome.

    Authors: Ahmad A. Tarhini, Haris Zahoor, Yan Lin, Usha Malhotra, Cindy Sander, Lisa H. Butterfield and John M. Kirkwood

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:39

    Published on:

  35. Content type: Research article

    There is little information regarding the composition of peripheral blood immunity in sarcoma patients and even less in the context of pediatric sarcomas. We describe the immune status using flow cytometry of ...

    Authors: Pooja Hingorani, Mary L. Maas, Michael P. Gustafson, Paul Dickman, Roberta H. Adams, Masayo Watanabe, Francis Eshun, James Williams, Matthew J. Seidel and Allan B. Dietz

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:35

    Published on:

  36. Content type: Short report

    Ipilimumab improves overall survival in a subset of patients with metastatic melanoma. Peripheral blood T cell receptor (TCR) repertoire diversity has been associated with favorable outcomes in patients with c...

    Authors: Michael A. Postow, Manuarii Manuel, Phillip Wong, Jianda Yuan, Zhiwan Dong, Cailian Liu, Solène Perez, Isabelle Tanneau, Marlène Noel, Anaïs Courtier, Nicolas Pasqual and Jedd D. Wolchok

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:23

    Published on:

  37. Content type: Commentary

    The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including posi...

    Authors: Lisa H Butterfield, Mary L Disis, Bernard A Fox, Samir N Khleif and Francesco M Marincola

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:8

    Published on:

  38. Content type: Research article

    We examined the phenotype and function of lymphocytes collected from the peripheral blood (PBL) and tumor (TIL) of patients with two different solid malignancies: colorectal cancer liver metastases (CRLM) and ...

    Authors: Magdalena Kovacsovics-Bankowski, Lana Chisholm, Jonna Vercellini, Christopher G Tucker, Ryan Montler, Daniel Haley, Philippa Newell, Jun Ma, Paul Tseng, Ronald Wolf, John T Vetto, Chet Hammill, Paul Hansen and Andrew D Weinberg

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:38

    Published on:

  39. Content type: Research article

    Oncolytic viruses represent a novel form of cancer immunotherapy. Vaccinia viruses encoding human T cell co-stimulatory molecules have demonstrated clinical activity in phase I clinical trials in patients with...

    Authors: Andrew Zloza, Dae Won Kim, Seunghee Kim-Schulze, Michael C Jagoda, Vladia Monsurro, Francesco M Marincola and Howard L Kaufman

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:1

    Published on:

  40. Content type: Research article

    We have developed a novel approach to categorize immunity in patients that uses a combination of whole blood flow cytometry and hierarchical clustering.

    Authors: Michael P Gustafson, Yi Lin, Betsy LaPlant, Courtney J Liwski, Mary L Maas, Stacy C League, Philippe R Bauer, Roshini S Abraham, Matthew K Tollefson, Eugene D Kwon, Dennis A Gastineau and Allan B Dietz

    Citation: Journal for ImmunoTherapy of Cancer 2013 1:7

    Published on:

  41. Content type: Research article

    Antigen-specific anti-tumor vaccines have demonstrated clinical efficacy, but immunological and clinical responses appear to be patient-dependent. We hypothesized that naturally-occurring differences in amino ...

    Authors: Jordan T Becker and Douglas G McNeel

    Citation: Journal for ImmunoTherapy of Cancer 2013 1:2

    Published on:

2017 Journal Metrics